Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model

Journal of Virology

Volumn 84, Issue 6, 2010, Pages 2983-2995

  Norton, Elizabeth B ^a   Clements, John D ^a   Voss, Thomas G ^a   Cárdenas Freytag, Lucia ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHOLERA TOXIN; CPG OLIGODEOXYNUCLEOTIDE; ESCHERICHIA ENTEROTOXIN; IMMUNOMODULATING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; ESCHERICHIA COLI; EXPERIMENTAL INFECTION; FEMALE; IMMUNE RESPONSE; IMMUNOMODULATION; INFECTION PREVENTION; INFLUENZA; INFLUENZA VIRUS; INFLUENZA VIRUS A; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS CULTURE; VIRUS LOAD; VIRUS PLAQUE; WEIGHT REDUCTION;

ADMINISTRATION, INTRANASAL; ANIMALS; BACTERIAL TOXINS; BODY WEIGHT; CHOLERA TOXIN; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; FEMALE; HUMANS; IMMUNE SYSTEM; IMMUNOLOGIC FACTORS; INFLAMMATION; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; LUNG; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL RATE; TREATMENT OUTCOME; VIRAL LOAD;

ESCHERICHIA COLI; MURINAE; MUS; ORTHOMYXOVIRIDAE;

EID: 77649095742     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01805-09     Document Type: Article

References (86)

1. Anonymous. 2008. Influenza fact sheet no. 211. World Health Organization, Geneva, Switzerland.
2. Bagley, K. C., S. F. Abdelwahab, R. G. Tuskan, and G. K. Lewis. 2006. Cholera toxin indirectly activates human monocyte-derived dendritic cells in vitro through the production of soluble factors, including prostaglandin E(2) and nitric oxide. Clin. Vaccine Immunol. 13:106-115.
3. Banerjee, B., K. J. Kelly, J. N. Fink, J. D. Henderson, Jr., N. K. Bansal, and V. P. Kurup. 2004. Modulation of airway inflammation by immunostimulatory CpG oligodeoxynucleotides in a murine model of allergic aspergillosis. Infect. Immun. 72:6087-6094.
4. Bowman, C. C., and J. D. Clements. 2001. Differential biological and adjuvant activities of cholera toxin and Escherichia coli heat-labile enterotoxin hybrids. Infect. Immun. 69:1528-1535.
5. Bromander, A., J. Holmgren, and N. Lycke. 1991. Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro. J. Immunol. 146:2908-2914.
6. Brown, D. M., A. M. Dilzer, D. L. Meents, and S. L. Swain. 2006. CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch. J. Immunol. 177:2888-2898.
7. Buchweitz, J. P., P. W. Karmaus, J. R. Harkema, K. J. Williams, and N. E. Kaminski. 2007. Modulation of airway responses to influenza A/PR/8/34 by Δ9-tetrahydrocannabinol in C57BL/6 mice. J. Pharmacol. Exp. Ther. 323: 675-683.
8. Cheng, E., L. Cardenas-Freytag, and J. D. Clements. 1999. The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT). Vaccine 18:38-49.
9. Choi, J. H., H. M. Ko, S. J. Park, K. J. Kim, S. H. Kim, and S. Y. Im. 2007. CpG oligodeoxynucleotides protect mice from lethal challenge with Candida albicans via a pathway involving tumor necrosis factor-alpha-dependent interleukin-12 induction. FEMS Immunol. Med. Microbiol. 51:155-162.
10. Clements, J. D., and R. A. Finkelstein. 1979. Isolation and characterization of homogeneous heat-labile enterotoxins with high specific activity from Escherichia coli cultures. Infect. Immun. 24:760-769.
11. Cluff, C. W., J. R. Baldridge, A. G. Stover, J. T. Evans, D. A. Johnson, M. J. Lacy, V. G. Clawson, V. M. Yorgensen, C. L. Johnson, M. T. Livesay, R. M. Hershberg, and D. H. Persing. 2005. Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge. Infect. Immun. 73:3044-3052.
12. Crowe, C. R., K. Chen, D. A. Pociask, J. F. Alcorn, C. Krivich, R. I. Enelow, T. M. Ross, J. L. Witztum, and J. K. Kolls. 2009. Critical role of IL-17RA in immunopathology of influenza infection. J. Immunol. 183:5301-5310.
13. Dawson, T. C., M. A. Beck, W. A. Kuziel, F. Henderson, and N. Maeda. 2000. Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus. Am. J. Pathol. 156:1951-1959.
14. Doherty, P. C., D. J. Topham, R. A. Tripp, R. D. Cardin, J. W. Brooks, and P. G. Stevenson. 1997. Effector CD4+ and CD8+ T-cell mechanisms in the control of respiratory virus infections. Immunol. Rev. 159:105-117.
15. Dong, L., I. Mori, M. J. Hossain, B. Liu, and Y. Kimura. 2003. An immunostimulatory oligodeoxynucleotide containing a cytidine-guanosine motif protects senescence-accelerated mice from lethal influenza virus by augmenting the T helper type 1 response. J. Gen. Virol. 84:1623-1628.
16. DuBois, A. B., L. C. Freytag, and J. D. Clements. 2007. Evaluation of combinatorial vaccines against anthrax and plague in a murine model. Vaccine 25:4747-4754.
17. Edwards, L., A. E. Williams, A. M. Krieg, A. J. Rae, R. J. Snelgrove, and T. Hussell. 2005. Stimulation via Toll-like receptor 9 reduces Cryptococcus neoformans-induced pulmonary inflammation in an IL-12-dependent manner. Eur. J. Immunol. 35:273-281.
18. Evans, K. D., and M. W. Kline. 1995. Prolonged influenza A infection responsive to rimantadine therapy in a human immunodeficiency virus-infected child. Pediatr. Infect. Dis. J. 14:332-334.
19. Gerhard, W. 2001. The role of the antibody response in influenza virus infection. Curr. Top. Microbiol. Immunol. 260:171-190.
20. GeurtsvanKessel, C. H., and B. N. Lambrecht. 2008. Division of labor between dendritic cell subsets of the lung. Mucosal Immunol. 1:442-450.
21. GeurtsvanKessel, C. H., M. A. Willart, L. S. van Rijt, F. Muskens, M. Kool, C. Baas, K. Thielemans, C. Bennett, B. E. Clausen, H. C. Hoogsteden, A. D. Osterhaus, G. F. Rimmelzwaan, and B. N. Lambrecht. 2008. Clearance of influenza virus from the lung depends on migratory langerin+CD11b- but not plasmacytoid dendritic cells. J. Exp. Med. 205:1621-1634.
22. Gonzalez-Juarrero, M., T. S. Shim, A. Kipnis, A. P. Junqueira-Kipnis, and I. M. Orme. 2003. Dynamics of macrophage cell populations during murine pulmonary tuberculosis. J. Immunol. 171:3128-3135.
23. Hamada, H., L. Garcia-Hernandez Mde, J. B. Reome, S. K. Misra, T. M. Strutt, K. K. McKinstry, A. M. Cooper, S. L. Swain, and R. W. Dutton. 2009. Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge. J. Immunol. 182:3469-3481.
24. Hammerbeck, D. M., G. R. Burleson, C. J. Schuller, J. P. Vasilakos, M. Tomai, E. Egging, F. R. Cochran, S. Woulfe, and R. L. Miller. 2007. Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats. Antivir. Res. 73:1-11.
25. Harker, J., A. Bukreyev, P. L. Collins, B. Wang, P. J. Openshaw, and J. S. Tregoning. 2007. Virally delivered cytokines alter the immune response to future lung infections. J. Virol. 81:13105-13111.
26. Harris, T. H., J. M. Mansfield, and D. M. Paulnock. 2007. CpG oligodeoxynucleotide treatment enhances innate resistance and acquired immunity to African trypanosomes. Infect. Immun. 75:2366-2373.
27. Ho, L. P., L. Denney, K. Luhn, D. Teoh, C. Clelland, and A. J. McMichael. 2008. Activation of invariant NKT cells enhances the innate immune response and improves the disease course in influenza A virus infection. Eur. J. Immunol. 38:1913-1922.
28. Holt, P. G., D. H. Strickland, M. E. Wikstrom, and F. L. Jahnsen. 2008. Regulation of immunological homeostasis in the respiratory tract. Nat. Rev. Immunol. 8:142-152.
29. James, C. M., M. Y. Abdad, J. P. Mansfield, H. K. Jacobsen, A. R. Vind, P. A. Stumbles, and E. J. Bartlett. 2007. Differential activities of alpha/beta IFN subtypes against influenza virus in vivo and enhancement of specific immune responses in DNA vaccinated mice expressing haemagglutinin and nucleoprotein. Vaccine 25:1856-1867.
30. Jia, W., H. Li, and Y. W. He. 2008. Pattern recognition molecule mindin promotes intranasal clearance of influenza viruses. J. Immunol. 180:6255-6261.
31. Jones, H. P., L. M. Hodge, K. Fujihashi, H. Kiyono, J. R. McGhee, and J. W. Simecka. 2001. The pulmonary environment promotes Th2 cell responses after nasal-pulmonary immunization with antigen alone, but Th1 responses are induced during instances of intense immune stimulation. J. Immunol. 167:4518-4526.
32. Jurk, M., and J. Vollmer. 2007. Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation. BioDrugs 21:387-401.
33. -/-) mutant mice. J. Exp. Med. 185:2157-2170.
34. Kawamura, Y. I., R. Kawashima, Y. Shirai, R. Kato, T. Hamabata, M. Yamamoto, K. Furukawa, K. Fujihashi, J. R. McGhee, H. Hayashi, and T. Dohi. 2003. Cholera toxin activates dendritic cells through dependence on GM1-ganglioside which is mediated by NF-κB translocation. Eur. J. Immunol. 33:3205-3212.
35. Kim, H. J., J. G. Lee, J. W. Kang, H. J. Cho, H. S. Kim, H. K. Byeon, and J. H. Yoon. 2008. Effects of a low concentration hypochlorous acid nasal irrigation solution on bacteria, fungi, and virus. Laryngoscope 118:1862-1867.
36. Kline, J. N., T. J. Waldschmidt, T. R. Businga, J. E. Lemish, J. V. Weinstock, P. S. Thorne, and A. M. Krieg. 1998. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J. Immunol. 160: 2555-2559.
37. Krieg, A. M., S. M. Efler, M. Wittpoth, M. J. Al Adhami, and H. L. Davis. 2004. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J. Immunother. 27:460-471.
38. Kuchroo, V. K., M. P. Das, J. A. Brown, A. M. Ranger, S. S. Zamvil, R. A. Sobel, H. L. Weiner, N. Nabavi, and L. H. Glimcher. 1995. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80:707-718.
39. La Gruta, N. L., K. Kedzierska, J. Stambas, and P. C. Doherty. 2007. A question of self-preservation: immunopathology in influenza virus infection. Immunol. Cell Biol. 85:85-92.
40. Lavelle, E. C., A. Jarnicki, E. McNeela, M. E. Armstrong, S. C. Higgins, O. Leavy, and K. H. Mills. 2004. Effects of cholera toxin on innate and adaptive immunity and its application as an immunomodulatory agent. J. Leukoc. Biol. 75:756-763.
41. Lavelle, E. C., E. McNeela, M. E. Armstrong, O. Leavy, S. C. Higgins, and K. H. Mills. 2003. Cholera toxin promotes the induction of regulatory T cells specific for bystander antigens by modulating dendritic cell activation. J. Immunol. 171:2384-2392.
42. Lee, J. B., J. E. Jang, M. K. Song, and J. Chang. 2009. Intranasal delivery of cholera toxin induces th17-dominated T-cell response to bystander antigens. PLoS One 4:e5190.
43. Le Goffic, R., J. Pothlichet, D. Vitour, T. Fujita, E. Meurs, M. Chignard, and M. Si-Tahar. 2007. Cutting edge: influenza A virus activates TLR3-dependent inflammatory and RIG-I-dependent antiviral responses in human lung epithelial cells. J. Immunol. 178:3368-3372.
44. Lu, X., J. D. Clements, and J. M. Katz. 2002. Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine. Vaccine 20:1019-1029.
45. Lund, F. E., S. Partida-Sanchez, B. O. Lee, K. L. Kusser, L. Hartson, R. J. Hogan, D. L. Woodland, and T. D. Randall. 2002. Lymphotoxin-alpha- deficient mice make delayed, but effective, T and B cell responses to influenza. J. Immunol. 169:5236-5243.
46. Lyons, C. R., and M. F. Lipscomb. 1983. Alveolar macrophages in pulmonary immune responses. I. Role in the initiation of primary immune responses and in the selective recruitment of T lymphocytes to the lung. J. Immunol. 130:1113-1119.
47. Maier, M., T. J. Seabrook, and C. A. Lemere. 2005. Modulation of the humoral and cellular immune response in Abeta immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT(R192G). Vaccine 23:5149-5159.
48. Marsolais, D., B. Hahm, K. H. Edelmann, K. B. Walsh, M. Guerrero, Y. Hatta, Y. Kawaoka, E. Roberts, M. B. Oldstone, and H. Rosen. 2008. Local not systemic modulation of dendritic cell S1P receptors in lung blunts virus-specific immune responses to influenza. Mol. Pharmacol. 74:896-903.
49. Martin, M., D. J. Metzger, S. M. Michalek, T. D. Connell, and M. W. Russell. 2001. Distinct cytokine regulation by cholera toxin and type II heat-labile toxins involves differential regulation of CD40 ligand on CD4(+) T cells. Infect. Immun. 69:4486-4492.
50. Matrosovich, M., T. Matrosovich, W. Garten, and H. D. Klenk. 2006. New low-viscosity overlay medium for viral plaque assays. Virol. J. 3:63.
51. Matsuo, K., T. Yoshikawa, H. Asanuma, T. Iwasaki, Y. Hagiwara, Z. Chen, S. E. Kadowaki, H. Tsujimoto, T. Kurata, and S. I. Tamura. 2000. Induction of innate immunity by nasal influenza vaccine administered in combination with an adjuvant (cholera toxin). Vaccine 18:2713-2722.
52. McKinstry, K. K., T. M. Strutt, A. Buck, J. D. Curtis, J. P. Dibble, G. Huston, M. Tighe, H. Hamada, S. Sell, R. W. Dutton, and S. L. Swain. 2009. IL-10 deficiency unleashes an influenza-specific Th17 response and enhances survival against high-dose challenge. J. Immunol. 182:7353-7363.
53. Miyagi, K., K. Kawakami, Y. Kinjo, K. Uezu, T. Kinjo, K. Nakamura, and A. Saito. 2005. CpG oligodeoxynucleotides promote the host protective response against infection with Cryptococcus neoformans through induction of interferon-gamma production by CD4+ T cells. Clin. Exp. Immunol. 140: 220-229.
54. Moyron-Quiroz, J. E., J. Rangel-Moreno, K. Kusser, L. Hartson, F. Sprague, S. Goodrich, D. L. Woodland, F. E. Lund, and T. D. Randall. 2004. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat. Med. 10:927-934.
55. Mozdzanowska, K., D. Zharikova, M. Cudic, L. Otvos, and W. Gerhard. 2007. Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse. Virol. J. 4:118.
56. Mutsch, M., W. Zhou, P. Rhodes, M. Bopp, R. T. Chen, T. Linder, C. Spyr, and R. Steffen. 2004. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350:896-903.
57. Potter, N. S., and C. V. Harding. 2001. Neutrophils process exogenous bacteria via an alternate class I MHC processing pathway for presentation of peptides to T lymphocytes. J. Immunol. 167:2538-2546.
58. Quan, F. S., R. W. Compans, H. H. Nguyen, and S. M. Kang. 2008. Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J. Virol. 82:1350-1359.
59. Rodriguez-Pinto, D. 2005. B cells as antigen presenting cells. Cell Immunol. 238:67-75.
60. Roux, X., C. Dubuquoy, G. Durand, T. L. Tran-Tolla, N. Castagne, J. Bernard, A. Petit-Camurdan, J. F. Eleouet, and S. Riffault. 2008. Sub-nucleocapsid nanoparticles: a nasal vaccine against respiratory syncytial virus. PLoS One 3:e1766.
61. Schmitz, N., M. Kurrer, M. F. Bachmann, and M. Kopf. 2005. Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection. J. Virol. 79:6441-6448.
62. Schwerbrock, N. M., E. A. Karlsson, Q. Shi, P. A. Sheridan, and M. A. Beck. 2009. Fish oil-fed mice have impaired resistance to influenza infection. J. Nutr. 139:1588-1594.
63. Shin, K., H. Wakabayashi, K. Yamauchi, S. Teraguchi, Y. Tamura, M. Kurokawa, and K. Shiraki. 2005. Effects of orally administered bovine lactoferrin and lactoperoxidase on influenza virus infection in mice. J. Med. Microbiol. 54:717-723.
64. Soriani, M., L. Bailey, and T. R. Hirst. 2002. Contribution of the ADP-ribosylating and receptor-binding properties of cholera-like enterotoxins in modulating cytokine secretion by human intestinal epithelial cells. Microbiology 148:667-676.
65. Reference deleted.
66. Stambas, J., C. Guillonneau, K. Kedzierska, J. D. Mintern, P. C. Doherty, and N. L. La Gruta. 2008. Killer T cells in influenza. Pharmacol. Ther. 120:186-196.
67. Takabayashi, K., L. Libet, D. Chisholm, J. Zubeldia, and A. A. Horner. 2003. Intranasal immunotherapy is more effective than intradermal immunotherapy for the induction of airway allergen tolerance in Th2-sensitized mice. J. Immunol. 170:3898-3905.
68. Tamura, S., and T. Kurata. 2004. Defense mechanisms against influenza virus infection in the respiratory tract mucosa. Jpn. J. Infect. Dis. 57:236-247.
69. Tano, L., and K. Tano. 2004. A daily nasal spray with saline prevents symptoms of rhinitis. Acta Otolaryngol. 124:1059-1062.
70. Tate, M. D., A. G. Brooks, and P. C. Reading. 2008. The role of neutrophils in the upper and lower respiratory tract during influenza virus infection of mice. Respir. Res. 9:57.
71. Tate, M. D., Y. M. Deng, J. E. Jones, G. P. Anderson, A. G. Brooks, and P. C. Reading. 2009. Neutrophils ameliorate lung injury and the development of severe disease during influenza infection. J. Immunol. 183:7441-7450.
72. Thitithanyanont, A., A. Engering, P. Ekchariyawat, S. Wiboon-ut, A. Limsalakpetch, K. Yongvanitchit, U. Kum-Arb, W. Kanchongkittiphon, P. Utaisincharoen, S. Sirisinha, P. Puthavathana, M. M. Fukuda, and S. Pichyangkul. 2007. High susceptibility of human dendritic cells to avian influenza H5N1 virus infection and protection by IFN-alpha and TLR ligands. J. Immunol. 179:5220-5227.
73. Trammell, R. A., and L. A. Toth. 2008. Genetic susceptibility and resistance to influenza infection and disease in humans and mice. Expert Rev. Mol. Diagn. 8:515-529.
74. Tuvim, M. J., S. E. Evans, C. G. Clement, B. F. Dickey, and B. E. Gilbert. 2009. Augmented lung inflammation protects against influenza A pneumonia. PLoS One 4:e4176.
75. Uddowla, S., L. C. Freytag, and J. D. Clements. 2007. Effect of adjuvants and route of immunizations on the immune response to recombinant plague antigens. Vaccine 25:7984-7993.
76. van der Laan, J. W., C. Herberts, R. Lambkin-Williams, A. Boyers, A. J. Mann, and J. Oxford. 2008. Animal models in influenza vaccine testing. Expert Rev. Vaccines 7:783-793.
77. van Duin, D., H. G. Allore, S. Mohanty, S. Ginter, F. K. Newman, R. B. Belshe, R. Medzhitov, and A. C. Shaw. 2007. Prevaccine determination of the expression of costimulatory B7 molecules in activated monocytes predicts influenza vaccine responses in young and older adults. J. Infect. Dis. 195: 1590-1597.
78. van Ginkel, F. W., R. J. Jackson, N. Yoshino, Y. Hagiwara, D. J. Metzger, T. D. Connell, H. L. Vu, M. Martin, K. Fujihashi, and J. R. McGhee. 2005. Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract. Infect. Immun. 73:6892-6902.
79. Waag, D. M., M. J. McCluskie, N. Zhang, and A. M. Krieg. 2006. A CpG oligonucleotide can protect mice from a low aerosol challenge dose of Burkholderia mallei. Infect. Immun. 74:1944-1948.
80. Waldman, R. H., J. O. Bond, L. P. Levitt, E. C. Hartwig, E. C. Prather, R. L. Baratta, J. S. Neill, and P. A. Small, Jr. 1969. An evaluation of influenza immunization: influence of route of administration and vaccine strain. Bull. W. H. O. 41:543-548.
81. Wikstrom, M. E., E. Batanero, M. Smith, J. A. Thomas, C. von Garnier, P. G. Holt, and P. A. Stumbles. 2006. Influence of mucosal adjuvants on antigen passage and CD4+ T cell activation during the primary response to airborne allergen. J. Immunol. 177:913-924.
82. Williams, A. E., L. Edwards, I. R. Humphreys, R. Snelgrove, A. Rae, R. Rappuoli, and T. Hussell. 2004. Innate imprinting by the modified heat-labile toxin of Escherichia coli (LTK63) provides generic protection against lung infectious disease. J. Immunol. 173:7435-7443.
83. Wong, J. P., M. E. Christopher, A. M. Salazar, R. M. Dale, L. Q. Sun, and M. Wang. 2007. Nucleic acid-based antiviral drugs against seasonal and avian influenza viruses. Vaccine 25:3175-3178.
84. Wong, J. P., L. P. Nagata, M. E. Christopher, A. M. Salazar, and R. M. Dale. 2005. Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs. Vaccine 23:2266-2268.
85. Zhao, Q., J. Temsamani, R. Z. Zhou, and S. Agrawal. 1997. Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. Antisense Nucleic Acid Drug Dev. 7:495-502.
86. Zheng, B. J., K. W. Chan, Y. P. Lin, G. Y. Zhao, C. Chan, H. J. Zhang, H. L. Chen, S. S. Wong, S. K. Lau, P. C. Woo, K. H. Chan, D. Y. Jin, and K. Y. Yuen. 2008. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc. Natl. Acad. Sci. U. S. A. 105:8091-8096